[one_fifth] 
Anton Bom, MD, PhD, FRCA
[/one_fifth] [four_fifth_last][framed_box]Anton Bom studied medicine at the Erasmus University, Rotterdam (The Netherlands). After having worked on cardiac afferent nerve fibres in cardiovascular reflexes at the Department of Cardiovascular Physiology in Düsseldorf (Germany), he joined the Department of Pharmacology of the Erasmus University and obtained his PhD cum laude for his thesis about the characterization of 5 hydroxytryptamine receptors in the cardiovascular system.
In 1989, he moved to Scotland to join the Department of Pharmacology of Organon Laboratories Ltd. This laboratory had a world-wide reputation for the development of the steroidal neuromuscular blocking agents.
In 1997 he developed the idea to use modified cyclodextrins to form high affinity complexes with steroidal neuromuscular blocking agents. This led to the development of sugammadex, a cyclodextrin derivative which can rapidly reverse the actions of steroidal neuromuscular blocking agents.
Since 2011, he works as an independent consultant for academic research and innovative drug design.[/framed_box]
[/four_fifth_last]